Search

everythinglearnresearchcommunity

for

Search:↓

Efforts to find a Canadian dermatologist in the US to prescribe H&W's topical finasteride for hair loss. The user is willing to fund a crowd-share effort to identify prospects.

Dermapen is considered more effective and easier to use than dermaroller and dermastamp for hair loss treatment, though results vary. Dermastamp is affordable but less convenient, while dermapen is more precise but can be bloody.

The conversation is about a person sharing before and after pictures of their hair loss treatment, which includes Minoxidil, Finasteride, and Dutasteride. They discuss their own hair loss, particularly the recession of their temporal points.

Current treatments for hair loss include finasteride, minoxidil, and derma rolling. New treatments like Breezula, PP405, and others are not expected until at least 2027 or later.

Low doses of dutasteride are as effective as higher doses for hair regrowth, with fewer side effects. Users find success taking it 2-3 times a week instead of daily.

A user is planning to use mesotherapy with 0.025% dutasteride for hair maintenance due to intolerance to finasteride. They seek clinics in Northern Germany, Sweden, or nearby countries for dutasteride scalp injections.

The user is considering switching from finasteride and RU58841 to dutasteride due to ongoing hair loss concerns. They are unsure if the hair loss is due to shedding or worsening condition.

A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.

A user diluted a Hims spray with Kirkland's minoxidil to lower finasteride concentration and has been applying it for nearly 3 months, noticing baby hairs at the temples. They also use a dermastamp, saw palmetto, and biotin supplements, and are seeking advice on their hair loss stage.

A user shared a new hair loss treatment protocol including topical dutasteride, latanoprost, caffeine, minoxidil, tretinoin, and triamcinolone acetonide. Others discussed the effectiveness and availability of these treatments, with some suggesting simpler oral alternatives.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The user reports significant hair regrowth after 2 months using a regimen of oral minoxidil, dutasteride, and a topical mix of minoxidil, RU58841, and caffeine. They apply the topical solution nightly and have not experienced any side effects.

A user experiencing hair loss since age 18 is considering switching from finasteride and minoxidil to dutasteride after poor results and lifestyle choices. They plan to improve their lifestyle and get blood work done to assess treatment effectiveness.

User shared 2-year progress with Dutasteride, 5mg oral minoxidil, and 7 months of RU58841 for hair growth. RU58841 was most effective, stopping itching and promoting significant growth.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.

Fluridil may decrease the number of androgen receptors in hair follicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.

A new human trial using an FDA-approved treatment for wound healing called Verteporfin, which may potentially be able to reverse scarring and regrow hair in that area. The trial is only lasting one month so far.

The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.

A user shared their success in getting a prescription for 0.1% Alfatradiol, a topical treatment for hair loss similar to finasteride but with fewer side effects. They found a pharmacy to compound it and will update on the results.

A user shared their 5-month hair transplant progress, having undergone a procedure with 4100 grafts at MedBlue in Istanbul for $3,600. They started taking oral minoxidil and finasteride daily after the transplant and use topical minoxidil with microneedling every two weeks, reporting positive results and no unwanted hair growth.

The user experienced hair thickening and regrowth using dutasteride on alternate days, oral minoxidil every third day, and daily hair massages, but is dealing with dandruff and inflammation. They are considering adjusting their minoxidil dosage and have started using ketoconazole shampoo and cupping therapy for additional benefits.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

Alfatradiol is considered safe but less effective than finasteride for hair loss. One user reported subtle regrowth using alfatradiol with finasteride and minoxidil, while another found alfatradiol ineffective.

The user has been using finasteride for almost two years but is considering switching to dutasteride and is curious about adding RU58841. They decide to stick with dutasteride due to concerns about RU58841's safety.

The conversation is about using Verteporfin with microneedling as a potential hair loss treatment that may regenerate hair follicles with minimal scarring. There are concerns about the optimal dosage and the DHT sensitivity of the new follicles.

A 22-year-old male is using topical dutasteride, minoxidil, tretinoin, and microneedling for hair loss, experiencing some side effects like mild ball pain and initial shedding but seeing progress in hair thickness. He plans to increase the dutasteride dose and has tried various treatments, including finasteride and RU58841, with differing side effects.